Table 4.

Infection Risk Analysis: Patients With Versus Patients Without Invasive Fungal Infection

Parameter	Univariate Comparison
	OR (95% CI)	P Value
Age	1.002 (.96–1.05)	.94
Female sex	0.46 (.13–1.58)	.21
CLL as underlying cancer	1.78 (.66–4.83)	.26
Ibrutinib daily dose	1.00 (.996–1.004)	.92
≥3 Prior treatment regimens	3.35 (1.22–9.21)	.02
Concurrent antitumor agents other than ibrutinib	2.33 (.74 – 7.31)	.15
Prior fludarabine	1.34 (.29–5.41)	.66
Neutropenia	2.92 (.71–12.09)	.14
Lymphopenia	3.36 (.98–11.55)	.054
Corticosteroid use	4.29 (1.40–13.18)	.01
Antimicrobial prophylaxis
PJP prophylaxis	1.63 (.47–5.66)	.44
Antifungal prophylaxis	2.12 (.28–15.91)	.46

Abbreviations: CI, confidence interval; CLL, chronic lymphocytic leukemia; OR, odds ratio; PJP, Pneumocystis jirovecii pneumonia.